Skip to content

Introducing 
AIM-IHC Breast Panel

Now Available on AISight® Image Management System

AI-Based Measurement Panel of Key Breast Cancer Biomarkers - HER2, ER, PR, and Ki-67

AIM IHC Breast Panel Workbook

Streamline breast cancer biomarker quantification on a single platform and implement this comprehensive AI-assisted panel to boost pathology workflow efficiency

Kaylee Workbook

Improve Workflow Efficiency

AI-generated scoring of Breast Cancer IHC is fully integrated in to the AISight® Image Management System reducing the time and effort required for manual assessments.

Kaylee Workbook (1)

Full Spectrum Biomarker Analysis

The AIM-IHC Breast Panel consolidates analysis for key critical biomarkers, including HER2, ER, PR, and Ki-67 - all available on a single platform

Accuracy

Fast and Accurate Quantification

Achieve reliable, and accurate biomarker quantification with zero-clicks in AI-predicted areas of invasive cancer - no longer compromise accuracy for speed

Untitled design (2)-2

Specifications:

  • Intended Use: Research Use Only
  • Indications: Breast Cancer
  • Clones: Agilent HercepTest, Roche Ventana 4B5
  • Scanners: Leica Aperio® AT2 and GT450, Hamamatsu NanoZoomer® s360
  • Inputs: Breast cancer biopsy, resection, and/or excision sample from primary, recurrent, or metastatic tumor (excluding in situ tumor)
  • Outputs: HER2 score (0, 1+, 2+, 3+), Area of invasive carcinoma, Additive multiple instance learning (aMIL) density heatmap

    AIM-HER2 Breast may be compatible with additional scanner types. Please contract us for more information

AIM-HER2 Breast

AIM-HER2 Breast is multi-clone and multi-scanner compatible

AIM IHC Workbook 2

AIM-Ki67 Breast 

AIM-Ki-67 Breast is multi-clone and multi-scanner compatible

ki


Specifications:

  • Intended Use: Research Use Only
  • Indications: Breast Cancer
  • Clones: Agilent Dako MIB-1; Roche Ventana 30-9
  • Scanners: Leica Aperio® AT2 and GT450; Philips UFS, Roche DP200 and DP600, Hamamatsu NanoZoomer® s360
  • Inputs: Breast cancer biopsy, resection, and/or excision sample from primary, recurrent, or metastatic tumor (excluding in situ tumor)
  • Outputs: Percent Ki-67+ positive cancer cells,  Area of invasive cancer,  Cell counts for Ki-67+ cancer cells and total cancer cells in invasive cancer regions

Specifications:

  • Intended Use: Research Use Only
  • Indications: Breast Cancer
  • Clones: Agilent Dako EP1; Roche Ventana SP1
  • Scanners: Leica Aperio® AT2 and GT450; Philips UFS, Roche DP200 and DP600, Hamamatsu NanoZoomer® s360
  • Inputs: Breast cancer biopsy, resection, and/or excision sample from primary, recurrent, or metastatic tumor (excluding in situ tumor)
  • Outputs: Percent ER+ positive cancer cells,  Area of invasive cancer,  Cell counts for ER+ cancer cells and total cancer cells in invasive cancer regions

AIM-ER Breast

AIM-ER Breast is multi-clone and multi-scanner compatible

ER

AIM-PR Breast

AIM-PR Breast is multi-clone and multi-scanner compatible

PR

Specifications:

  • Intended Use: Research Use Only
  • Indications: Breast Cancer
  • Clones: Agilent Dako PgR 636; Roche Ventana 1E2
  • Scanners: Leica Aperio® AT2 and GT450; Philips UFS, Roche DP200 and DP600, Hamamatsu NanoZoomer® s360
  • Inputs: Breast cancer biopsy, resection, and/or excision sample from primary, recurrent, or metastatic tumor (excluding in situ tumor)
  • Outputs: Percent PR+ positive cancer cells,  Area of invasive cancer,  Cell counts for PR+ cancer cells and total cancer cells in invasive cancer regions

CASE STUDY

AI-Assisted Titer Selection in Early Assay Development

  • PathAI deployed IHC Explore on prostate cancer specimens stained with a novel, in-development assay
  • IHC Explore quantifies staining intensity at single-cell resolution, enabling rapid assay characterization and titer optimization​
  • Continuous staining intensity measurement provides added value for next-generation biomarkers and precision medicine strategies

HER2 Scoring Heatmaps - Additional Information

Additive heatmaps highlight tissue patterns features that most contribute to AIM-HER2's score prediction. Pathologists are able to more confidently assess HER2 expression, especially in borderline cases with more slide-level heterogeneity as they can quickly and more easily focus on the most critical features and slide areas.

FPO-AIM-HER2-scoring-heatmap-1
FPO-AIM-HER2-scoring-heatmap-2

AIM-IHC Breast Panel, AIM-HER2, AIM-ER, AIM-PR, and AIM-Ki-67 are for research use only. Not for use in diagnostic procedures.

AISight is for Research Use Only in the US; AISight Dx is CE-IVD marked in Europe, UK and Switzerland.